SLC5A2 and Hypoglycemia: Insulin sensitizers like thiazolidinediones (TZDs), secretagogues, and sodium-glucose cotransporter-2 (SGLT2) inhibitors can cause weight gain, hepatotoxicity, fluid retention, and hypoglycemia, limiting their long-term utility and patient compliance [4,5].